Spectrum Pharmaceuticals Inc (SPPI)

10.10
0.00 (0.00)
NASDAQ : Health Care
Prev Close 10.10
Open 10.10
Day Low/High 10.05 / 10.19
52 Wk Low/High 4.14 / 7.74
Volume 1.14M
Avg Volume 886.50K
Exchange NASDAQ
Shares Outstanding 84.46M
Market Cap 858.93M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Spectrum Pharmaceuticals To Present Corporate Update At The 2017 Southern California Investor Conference In Newport Beach On Thursday, August 24th

Spectrum Pharmaceuticals To Present Corporate Update At The 2017 Southern California Investor Conference In Newport Beach On Thursday, August 24th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Announces Initiation Of The Registrational Phase 3 Trial Of Qapzola™ (apaziquone) In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Spectrum Pharmaceuticals Announces Initiation Of The Registrational Phase 3 Trial Of Qapzola™ (apaziquone) In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today the Company has...

Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results...

Spectrum Pharmaceuticals Announces Completion Of Enrollment In The Phase 3 Pivotal Study (ADVANCE) Of ROLONTIS™ (eflapegrastim), A Novel Long-Acting GCSF

Spectrum Pharmaceuticals Announces Completion Of Enrollment In The Phase 3 Pivotal Study (ADVANCE) Of ROLONTIS™ (eflapegrastim), A Novel Long-Acting GCSF

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today the Company has...

Spectrum Pharmaceuticals Highlights Results Of A Combination Study Of FOLOTYN® (pralatrexate Injection) Plus Romidepsin Presented At The 14th International Conference On Malignant Lymphoma (14-ICML) Meeting

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced the presentation of data...

Spectrum Pharmaceuticals Highlights Three Abstracts Of Clinical Data At The 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago, Illinois, June 2-6, 2017

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced presentations of...

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2017 Global Healthcare Conference On June 6th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2017 Health Care Conference On May 17

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.

Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results...

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.

Spectrum Pharmaceuticals To Present Corporate Update At The 42nd Annual Deutsche Bank Health Care Conference On May 4

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Announces First Quarter 2017 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs.

Spectrum Pharmaceuticals Highlights Preclinical Data Of ROLONTIS™ (eflapegrastim) At The American Association For Cancer Research (AACR) Annual Meeting

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced the presentation of preclinical...

Spectrum Pharmaceuticals Highlights Three Abstracts On ROLONTIS™ (eflapegrastim) And BELEODAQ® (belinostat) For Injection At The American Association For Cancer Research (AACR) Annual Meeting In Washington, D.C., April 1-5, 2017

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of...

Spectrum Pharmaceuticals Announces Initiation Of A Phase 2 Trial Of Poziotinib In Non-Small Cell Lung Cancer Patients With EGFR Exon 20 Insertion Mutations

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that the University of...

First Week Of November 17th Options Trading For Spectrum Pharmaceuticals (SPPI)

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the November 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Premarket Movers: Spectrum, BioCryst, Curis

Biotech Premarket Movers: Spectrum, BioCryst, Curis

Spectrum Pharmaceuticals, BioCryst Pharmaceuticals and Curis were among the biotech stock movers in premarket trading on Thursday.

Spectrum Pharmaceuticals Reports Fourth Quarter 2016 And Full Year 2016 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results...

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2016 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...

First Week of SPPI April 21st Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the April 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new April 21st contracts and identified the following call contract of particular interest.

Spectrum Pharmaceuticals To Present Corporate Update At The 2017 RBC Capital Markets Global Healthcare Conference On February 23rd

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Commit To Purchase Spectrum Pharmaceuticals At $3, Earn 16.6% Annualized Using Options

Commit To Purchase Spectrum Pharmaceuticals At $3, Earn 16.6% Annualized Using Options

Investors eyeing a purchase of Spectrum Pharmaceuticals Inc stock, but cautious about paying the going market price of $4.47/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $3 strike, which has a bid at the time of this writing of 20 cents.

Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib In Lung Cancer At The 17th IASLC World Conference On Lung Cancer

Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib In Lung Cancer At The 17th IASLC World Conference On Lung Cancer

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced the oral presentation of data...

Spectrum Pharmaceuticals Highlights Survival Advantage In A Case Match Control Analysis Of The PROPEL Study With FOLOTYN® (pralatrexate Injection) at The 58th Annual Meeting Of The American Society Of Hematology (ASH)

Spectrum Pharmaceuticals Highlights Survival Advantage In A Case Match Control Analysis Of The PROPEL Study With FOLOTYN® (pralatrexate Injection) at The 58th Annual Meeting Of The American Society Of Hematology (ASH)

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced the presentation of data from a...

Spectrum Pharmaceuticals Highlights Five Abstracts On ROLONTIS™ (eflapegrastim) And Poziotinib At The San Antonio Breast Cancer Symposium (SABCS) In San Antonio, Texas, December 6-10, 2016

Spectrum Pharmaceuticals Highlights Five Abstracts On ROLONTIS™ (eflapegrastim) And Poziotinib At The San Antonio Breast Cancer Symposium (SABCS) In San Antonio, Texas, December 6-10, 2016

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of...

Spectrum Pharmaceuticals Highlights Four Abstracts At The 58th Annual Meeting Of The American Society Of Hematology (ASH) In San Diego, California, December 3-6, 2016

Spectrum Pharmaceuticals Highlights Four Abstracts At The 58th Annual Meeting Of The American Society Of Hematology (ASH) In San Diego, California, December 3-6, 2016

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of...

TheStreet Quant Rating: C- (Hold)